# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K053446

# B. Purpose for Submission:

The Gen-Probe APTIMA® Assay for Chlamydia trachomatis (ACT) is a nucleic acid amplification test (NAAT) intended for the qualitative detection of ribosomal RNA from Chlamydia trachomatis (CT) in endocervical, male urethral and vaginal swab specimens and in female and male urine specimens. The assay originally received FDA clearance in 2004 (K043072). The current application is for the additional indication of testing specimens collected and processed with the Cytyc ThinPrep 2000 System and the SurePath PrepStain System. New SurePath and PreservCyt labeling for the approved ancillary liquid pap Specimen Transfer Kit is included in the current submission.

C. Measurand: Chlamydia trachomatis (CT) ribosomal RNA

D. Type of Test: NAAT   
E. Applicant: GEN-PROBE, INC.   
F. Proprietary and Established Names: GEN-PROBE® APTIMA® Assay for Chlamydia trachomatis   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MKZ</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 866.3210</td><td rowspan=1 colspan=1>Microbiology (83)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

The APTIMA Assay for Chlamydia trachomatis is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) in clinician-collected endocervical, vaginal and male urethral swab specimens, patient-collected vaginal swab specimens, and female and male urine specimens. The assay is also intended for use with the testing of gynecological specimens collected in the PreservCyt $\textsuperscript { \textregistered }$ Solution and processed with the Cytyc ThinPrep $\textsuperscript { \textregistered }$ 2000 System. The assay may be used to test specimens from symptomatic and asymptomatic individuals to aid in the diagnosis of chlamydial urogenital disease.

\*Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated. The vaginal swab specimen collection kit is not for home use.

2. Indication(s) for use: See Intended Use above.

3. Special conditions for use statement(s): This device is for prescription use only

4. Special instrument requirements: Gen-Probe DTS® System

# I. Device Description:

The GEN-PROBE® APTIMA® Assay for Chlamydia trachomatis is a nucleic acid amplification test (NAAT). See Test Principle below for more details.

# J. Substantial Equivalence Information:

Addition of a PreservCyt (PC) specimen indication to the previously cleared device. Collection device and media are different, as are specimen handling and storage conditions.

# K. Standard/Guidance Document Referenced (if applicable):

Not Applicable

# L. Test Principle:

The GEN-PROBE APTIMA Assay for Chlamydia trachomatis combines the technologies of target capture, Transcription-Mediated Amplification (TMA), and Hybridization Protection Assay (HPA). During target capture, rRNA molecules are isolated from specimens by capture oligomers on magnetic microparticles. After target capture, the specimens are ready for TMA. The GEN-PROBE APTIMA Assay for Chlamydia trachomatis reaction replicates a specific region of the 16S rRNA from C. trachomatis via DNA intermediates. Detection of the rRNA amplicons is achieved using single-stranded chemiluminescent DNA probes, which are labeled with different acridinium ester molecules. The labeled DNA probes combine with amplicon to form stable RNA:DNA hybrids and light emitted from the labeled RNA:DNA hybrids is reported as Relative Light Units (RLU). Assay results are determined by a cut-off based on the total RLU.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

PreservCyt specimen within-laboratory precision with the ACT assay was determined by spiking PreservCyt vials with 20 CT IFU per vial (0.1 IFU per reaction) and 100 CT IFU per vial (0.5 IFU per reaction). Vials containing $1 { , } 0 0 0 \mathrm { C T }$ IFU per vial (5 IFU per reaction) and unspiked PreservCyt vials were tested as positive and negative controls. Ten vials spiked at each IFU level and ten unspiked vials were divided between two operators. The operators vortexed the vials and then transferred 14 aliquots ( $1 . 0 \mathrm { m L }$ each) per vial into 14 APTIMA Transfer Tubes as per the APTIMA Specimen Transfer Kit package insert. The operators were blinded to the samples' titers. Each of the resulting Pap-STM samples was tested once in the ACT assay. A total of five runs were performed over a five day period for 140 results at each IFU level. The results are summarized below:

Ta a to 1000 IFU/20 ml of CT cell8   

<table><tr><td rowspan=2 colspan=1>PanelMember</td><td rowspan=2 colspan=1>LIFU/20mLPreeervCyt</td><td rowspan=2 colspan=1>IFU!rxn</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>Agreed</td><td rowspan=2 colspan=1>%Agmt.</td><td rowspan=2 colspan=1>MeanRLU(x1000)</td><td rowspan=1 colspan=2>within-Operator</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Operator</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD(x1000)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD(x1000)</td><td rowspan=1 colspan=1>cv (%)</td><td rowspan=1 colspan=1>SD(x1000)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD(x1000)</td><td rowspan=1 colspan=1>cV (%)</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>6501.7</td><td rowspan=1 colspan=1>734.8</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>546.9</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>916</td><td rowspan=1 colspan=1>14.1</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>138*</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>6337.7</td><td rowspan=1 colspan=1>1054.7</td><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>947.2</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>1417.6</td><td rowspan=1 colspan=1>224</td></tr><tr><td rowspan=1 colspan=1>c</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>6521.9</td><td rowspan=1 colspan=1>909</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>247.1</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>393.9</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1021</td><td rowspan=1 colspan=1>15.7</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>N/A</td></tr></table>

" discordant results were one negative result and 1 equlvocal resuft discordantreuwere Incuded In theignal varability analyss.

b. Linearity/assay reportable range: Not Applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not Applicable

# d. Detection limit:

A study was performed that showed the ACT Assay detected CT cells at the analytical sensitivity claim (I IFU/assay) for 3 replicates of each of $1 5 \mathrm { C T }$ serovars tested in PC media. See results below:

Table 5.5-10: PreservCyt Analytical Sensitivity for Detection of CT   

<table><tr><td rowspan=2 colspan=1>Serovar</td><td rowspan=2 colspan=1>IFU/Assay</td><td rowspan=1 colspan=2>Replicate 1</td><td rowspan=1 colspan=2>Replicate 2</td><td rowspan=1 colspan=2>Replicate 3</td></tr><tr><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,651,0005,882,0005,597,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,855,0005,923,0005,820,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,812,0005,777,0005,637,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,687,0005,657,0005,866,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,579,0005,856,0005,540,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,575,0005,756,0005,510,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>Ba</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,513,0005,647,0005,613,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,599,0005,661,0005,474,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,758,0005,588,0005,662,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,506,0005,539,0005,527,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,456,0005,576,0005,623,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,521,0005,326,0005,421,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,443,0005,406,0005,508,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,672,0005,436,0005,565,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,627,0005,422,0005,573,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,445,0005,501,0005,653,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,529,0005,269,0005,575,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,412,0005,480,0005,614,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,451,0005,609,0005,511,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,424,0005,589,0005,423,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,351,0005,556,0005,386,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>G</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,558,0005,360,0005,588,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,589,0005,389,0005,601,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,485,0005,543,0005,519,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr></table>

Table 5.5-10: (con't) PreservCyt Analytical Sensitivity for Detection of CT   

<table><tr><td rowspan=2 colspan=1>Serovar</td><td rowspan=2 colspan=1>IFU/Assay</td><td rowspan=1 colspan=2>Replicate 1</td><td rowspan=1 colspan=2>Replicate 2</td><td rowspan=1 colspan=2>Replicate 3</td></tr><tr><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=2>RLU      Result</td><td rowspan=1 colspan=2>RLU     Result</td></tr><tr><td rowspan=1 colspan=1>H</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,593,0005,591,0005,675,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,746,0005,668,0005,594,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,661,0005,685,0005,681,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,764,0006,122,0005,742,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,897,0005,924,0005,594,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,952,0005,873,0005,621,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>J</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,457,0005,137,0005,348,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,017,0005,290,0005,477,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,334,0005,373,0005,501,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>K</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,317,0005,357,0005,532,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,065,0005,450,0005,619,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,155,0005,495,0005,346,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L1</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,300,0005,452,0005,277,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,332,0005,431,0004,955,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,391,0005,517,0005,203,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L2</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,317,0005,419,0004,979,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,401,0005,320,0005,281,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,394,0005,117,0005,317,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L3</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,534,0005,277,0005,329,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,416,0005,369,0005,109,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,394,0005,198,0005,337,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr></table>

Table 5.5-11: SurePath Analytical Sensitivity for Detection of CT   

<table><tr><td rowspan=2 colspan=1>Serovar</td><td rowspan=2 colspan=1>IFU/Assay</td><td rowspan=1 colspan=2>Replicate 1</td><td rowspan=1 colspan=2>Replicate 2</td><td rowspan=1 colspan=2>Replicate 3</td></tr><tr><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,707,0005,316,0005,592,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,224,0005,835,0005,364,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,371,0005,809,0005,495,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,772,0005,747,0005,544,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,572,0005,467,0005,638,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,763,0005,216,0005,876,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>Ba</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,432,0005,158,0005,453,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,495,0005,328,0005,619,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,125,0005,143,0005,761,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,917,0005,825,0005,624,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,874,0005,767,0005,748,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,712,0005,661,0005,644,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,903,0005,648,0005,883,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,933,0005,950,0005,704,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,967,0005,815,0005,905,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,818,0005,743,0005,835,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,771,0005,611,0005,715,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,756,0005,910,0005,610,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,491,0005,538,0004,394,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,573,0005,854,0005,446,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,345,0005,396,0005,057,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>G</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,423,0005,762,0005,725,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,523,0005,744,0005,526,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,561,0005,646,0005,497,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr></table>

Table 5.5-11: (con't) SurePath Analytical Sensitivity for Detection of CT   

<table><tr><td rowspan=2 colspan=1>Serovar</td><td rowspan=2 colspan=1>IFU/Assay</td><td rowspan=1 colspan=2>Replicate 1</td><td rowspan=1 colspan=2>Replicate 2</td><td rowspan=1 colspan=2>Replicate 3</td></tr><tr><td rowspan=1 colspan=1>RLU</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=2>RLU      Result</td><td rowspan=1 colspan=2>RLU     Result</td></tr><tr><td rowspan=2 colspan=1>H</td><td rowspan=2 colspan=1>101.00.1</td><td rowspan=2 colspan=1>5,224,0005,428,0005,322,000</td><td rowspan=2 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,437,000</td><td rowspan=2 colspan=1>CT+CT+CT+</td><td rowspan=2 colspan=1>5,356,0005,176,0005,202,000</td><td rowspan=2 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>5,233,0005,457,000</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,873,0006,078,0005,786,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>6,011,0006,041,0005,873,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>6,046,0005,917,0005,795,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>J</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,846,0005,454,0005,331,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,700,0005,252,0005,271,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,695,0005,334,0005,437,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>K</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,179,0004,430,0004,954,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,123,0005,034,0005,205,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,155,0005,495,0005,346,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L1</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>4,914,0004,957,0005,221,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>4,853,0004,987,0005,334,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>4,999,0005,228,0005,116,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L2</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,206,0005,246,0005,119,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,141,0005,462,0005,129,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,213,0005,055,0004,862,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr><tr><td rowspan=1 colspan=1>L3</td><td rowspan=1 colspan=1>101.00.1</td><td rowspan=1 colspan=1>5,183,0005,165,0004,761,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,265,0004,996,0004,892,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td><td rowspan=1 colspan=1>5,354,0005,076,0004,903,000</td><td rowspan=1 colspan=1>CT+CT+CT+</td></tr></table>

# e. Analytical specificity:

The Chlamydia species were used to evaluate the analytical specificity of the ACT Assay. A total of 3 culture isolates were tested in the liquid Pap media. None of the 3 culture isolates produced a positive result in the ACT Assay. See results below:

Table 5.5.7.1-01: Specificity of the ACT Assay with PreservCyt Samples   

<table><tr><td rowspan=1 colspan=1>PHYLOGENETICCROSS-SECTION</td><td rowspan=1 colspan=1>GPNo.</td><td rowspan=1 colspan=1>ATCCNo.</td><td rowspan=1 colspan=1>ConcentrationTested/Assay</td><td rowspan=1 colspan=1>Rep#</td><td rowspan=1 colspan=1>Results(RLU)</td></tr><tr><td rowspan=1 colspan=1>Chlamydia psittaci</td><td rowspan=1 colspan=1>1557</td><td rowspan=1 colspan=1>VR601</td><td rowspan=1 colspan=1>7.9 x 10* cells</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>00</td></tr><tr><td rowspan=1 colspan=1>Chlamydia psittaci</td><td rowspan=1 colspan=1>768</td><td rowspan=1 colspan=1>VR629</td><td rowspan=1 colspan=1>1      x     10+CELD50/0.2 m1</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1,0001,000</td></tr><tr><td rowspan=1 colspan=1>Chlamydia pneumoniae</td><td rowspan=1 colspan=1>1404</td><td rowspan=1 colspan=1>VR1360</td><td rowspan=1 colspan=1>4.0 x 103cells</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>00</td></tr></table>

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: Not Applicable

3. Clinical studies:

A prospective multi-center clinical study was conducted to evaluate the use of the PreservCyt Solution (a component of the ThinPrep 2000 System) as an alternative medium for gynecological specimens for the detection of CT by the APTIMA CT Assay. One thousand six hundred forty-seven (1,647) symptomatic and asymptomatic female subjects attending OB/GYN, family planning, public health, women's, and STD clinics were evaluated in the clinical study. Of the 1,647 evaluable subjects, 1,288 were asymptomatic subjects and 359 were symptomatic subjects. Subjects were enrolled from sites with CT prevalence that ranged from $2 . 8 \%$ to $1 4 . 0 \%$ .

Two specimens were collected from each eligible subject: one PreservCyt Solution liquid Pap specimen and one endocervical swab specimen. PreservCyt Solution liquid Pap specimens were collected with the spatula/cyto-brush or a broom-like brush cervical sampling device. The distribution of cervical sampling devices is summarized in Table 4 by specimen collection site and overall.

PreservCyt Solution liquid Pap specimens were processed in accordance with the ThinPrep 2000 Processor Operator's Manual and APTIMA Specimen Transfer Kit Package Insert. After processing the PreservCyt Solution liquid Pap specimen with the ThinPrep 2000 Processor, the specimen was transferred into the APTIMA Specimen Transfer Kit for testing with the APTIMA CT Assay.

Sensitivity and specificity of the APTIMA CT Assay in PreservCyt Solution liquid Pap specimens were calculated by comparing results to a patient infected status algorithm. The algorithm included APTIMA Combo 2 Assay and APTIMA CT Assay results in endocervical swab specimens. Both reference NAATs were required to be positive to establish an infected patient status. At least one reference NAAT was required to be negative to establish a non-infected patient status. Table 7e summarizes the frequency of test outcomes for the two reference NAATs.

Table 5b shows the sensitivities and specificities of the APTIMA CT Assay by symptom status and overall. Overall sensitivity was $9 5 . 6 \%$ (86/90). In symptomatic and asymptomatic subjects, sensitivities were $9 6 . 7 \%$ (29/30) and $9 5 . 0 \%$ (57/60), respectively. Overall specificity was $9 8 . 8 \%$ (1539/1557). In symptomatic and asymptomatic subjects, specificities were $9 8 . 8 \%$ (325/329) and $9 8 . 9 \%$ (1214/1228), respectively.

Table 6b shows the sensitivities and specificities of the APTIMA CT Assay by specimen collection site and overall. Sensitivities ranged from $9 2 . 9 \%$ to $100 \%$ . Specificities ranged from $9 6 . 5 \%$ to $100 \%$ .

Table 4. Distribution of Cervical Sampling Device Used for PreservCyt Solution Liquid Pap Specimens   

<table><tr><td rowspan=2 colspan=1>Cervical Sampling Device Used</td><td rowspan=1 colspan=6>Clinical Collection Site</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Spatula/Cytobrush</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>475</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>364</td><td rowspan=1 colspan=1>1307</td></tr><tr><td rowspan=1 colspan=1>Broom-Type Device</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>340</td></tr></table>

Table 7e. PreservCyt Solution Liquid Pap Specimen Analysis for Patient Infected Status   

<table><tr><td rowspan=2 colspan=1>Patient Infected Status</td><td rowspan=1 colspan=2>Endocervical Swab</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=2>Symptom Status</td></tr><tr><td rowspan=1 colspan=1>APTIMA COMBO2 Assay</td><td rowspan=1 colspan=1>APTIMA CTAssay</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Symptomatic</td><td rowspan=1 colspan=1>Asymptomatic</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>322</td><td rowspan=1 colspan=1>1214</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=6>Total                                                             359                1288</td></tr></table>

TavSa Overall for PreservCyt Solution Liquid Pap Specimens   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>APTIMA CTPreservCytSolution result</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>-1+</td><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>Sensitivity (%)(95% CI)</td><td rowspan=1 colspan=1>Specificity (%)(95% CI)</td></tr><tr><td rowspan=3 colspan=1>Symptomatic</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=3 colspan=1>96.7 (29/30)(82.8  99.9)</td><td rowspan=3 colspan=1>98.8 (325/329)(96.9-99.7)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>319</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>322</td></tr><tr><td rowspan=3 colspan=1>Asymptomatic</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13</td><td rowspan=3 colspan=1>95.0 (57/60)(86.199.0)</td><td rowspan=3 colspan=1>98.9 (1214/1228)(98.1-99.4)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1201</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1214</td></tr><tr><td rowspan=3 colspan=1>All</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=3 colspan=1>95.6 (86/90)(89.0 - 98.8)</td><td rowspan=3 colspan=1>98.8 (1539/1557)(98.2 - 99.3)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1520</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1536</td></tr></table>

$+ / + =$ u/ln the APTIMA CT Assay $+ / - s$ vvil apesuANegativicale the APTIMA CT Assay $- I + =$ Nevlu/Poal the APTIMA CT Assay $- l - =$ uu APTIMA CT Assay

a Clinical Site and Overall for PreservCyt Solution Liquid Pap Specimens   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>APTIMA CTPreservCytSolutionResult</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>-/+</td><td rowspan=1 colspan=1>--</td><td rowspan=1 colspan=1>Prev(9%</td><td rowspan=1 colspan=1>Sensitivity(%) (95% C.I.)</td><td rowspan=1 colspan=1>Specificity (%)(95% C.I.)</td><td rowspan=1 colspan=1>PPV (%)</td><td rowspan=1 colspan=1>NPV (%)</td></tr><tr><td rowspan=3 colspan=1>1</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=3 colspan=1>14.0</td><td rowspan=3 colspan=1>100 (14/14)(76.8 100)</td><td rowspan=3 colspan=1>96.5 (83/88)(90.199.3)</td><td rowspan=3 colspan=1>82.4</td><td rowspan=3 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>83</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=3 colspan=1>2</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=3 colspan=1>3.2</td><td rowspan=3 colspan=1>100 (4/4)(39.8 - 100)</td><td rowspan=3 colspan=1>100 (120/120)(97.0  100)</td><td rowspan=3 colspan=1>100</td><td rowspan=3 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>118</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>118</td></tr><tr><td rowspan=3 colspan=1>3</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=3 colspan=1>6.5</td><td rowspan=3 colspan=1>93.5 (29/31)(78.6 - 99.2)</td><td rowspan=3 colspan=1>98.6 (438/444)(97.1-98.5)</td><td rowspan=3 colspan=1>82.9</td><td rowspan=3 colspan=1>99.5</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>436</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>442</td></tr><tr><td rowspan=3 colspan=1>4</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=3 colspan=1>2.8</td><td rowspan=3 colspan=1>100 (8/8)(63.1 - 100)</td><td rowspan=3 colspan=1>98.6 (275/279)(96.4-98.6)</td><td rowspan=3 colspan=1>66.7</td><td rowspan=3 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>271</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>275</td></tr><tr><td rowspan=3 colspan=1>5</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=3 colspan=1>4.7</td><td rowspan=3 colspan=1>92.9 (13/14)(66.1-99.8)</td><td rowspan=3 colspan=1>98.9 (280/283)(96.9 99.8)</td><td rowspan=3 colspan=1>81.3</td><td rowspan=3 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>275</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>278</td></tr><tr><td rowspan=3 colspan=1>6</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=3 colspan=1>5.2</td><td rowspan=3 colspan=1>94.7 (18/19)(74.0  99.9)</td><td rowspan=3 colspan=1>99.4 (343/345)(97.9 99.9)</td><td rowspan=3 colspan=1>90.0</td><td rowspan=3 colspan=1>99.7</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>337</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>338</td></tr><tr><td rowspan=3 colspan=1>All</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=3 colspan=1>5.5</td><td rowspan=3 colspan=1>95.6 (86/90)(89.0 - 98.8)</td><td rowspan=3 colspan=1>98.8 (1539/1557)(98.299.3)</td><td rowspan=3 colspan=1>82.7</td><td rowspan=3 colspan=1>99.7</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1520</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1536</td></tr></table>

$+ 1 + =$ Posiivical swabee esulhTABsay/Posivnvical swaseceu n the APTIMA CT Assay $+ 1 - =$ PalAM/Neaivvin the APTIMA CT Assay $\mathbb { - } / \mathbb { + } =$ Negatvicalaece esult heTACOBsay/Postivicalaeceln the APTIMA CT Assay $- t - =$ u APTIMA CT Assay

4. Clinical cut-off:

Not Applicable

5. Expected values/Reference range:

The prevalence of C. trachomatis disease in patient populations depends on risk factors such as age, gender, the presence of symptoms, the type of clinic, and the test method. A summary of the prevalence of $C .$ . trachomatis as determined by the APTIMA® Assay for Chlamydia trachomatis (ACT) results on PreservCyt liquid Pap specimens is shown below by clinical site and overall.

Table 1b. Prevalence of C. trachomatis by Clinical Site and Overall as Determined by APTIMA CT Assay Results Using PreservCyt Solution Liquid Pap Specimens   

<table><tr><td>Site</td><td colspan="2">% (#positive / #tested)</td></tr><tr><td>1</td><td>17.0</td><td>(17/100)</td></tr><tr><td>2</td><td>3.2</td><td>(4/124)</td></tr><tr><td>3</td><td>7.4</td><td>(35/475)</td></tr><tr><td>4</td><td>4.2</td><td>(12/287)</td></tr><tr><td>5</td><td>5.4</td><td>(16/287)</td></tr><tr><td>6</td><td>5.5</td><td>(20/364)</td></tr><tr><td>All</td><td>6.3</td><td>(104/1647)</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

1. The submitted information in this premarket notification is complete and supports a substantial equivalence decision.